Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study
NCT02472717 on ClinicalTrials.gov · last registry update 2017-07-17
Withdrawn before anyone was enrolled. Completed October 2016. liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- WITHDRAWN
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor type
- Other
- Enrollment
- 0
- Started
- 2015-05
- Primary completion
- 2016-10 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo
Conditions studied
Psoriatic Arthritis · Psoriasis · Impaired Glucose Tolerance · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.